ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
24 announcements
Consolidated sales rose about 14% to ₹2,910 Cr and EBITDA margin reached 22.97%, inside the 22-23% guided band. Management reiterated FY27 guidance without a raise.
Ipca Laboratories Ltd reported revenue from operations of ₹2,910 Cr (+13.8% YoY) and net profit of ₹389.3 Cr (+38.8% YoY) for Q2 FY27.
Ipca Laboratories board meeting set for 5 November 2026 to approve Q2 and H1 FY27 unaudited results. Insider trading window remains closed until two days after declaration.
Ipca Laboratories Ltd submitted its quarterly shareholding pattern for the period ended September 30, 2026, in compliance with Regulation 31(1)(b) of the SEBI Listing Regulations.
Ipca reported strong Q1FY27 with 21% consolidated revenue growth and EBITDA margins expanding 449bps to 22.88%. Management raised full-year growth and margin guidance based on robust generic and domestic performance.
Ipca Laboratories held its 76th Annual General Meeting, covering the adoption of financial statements, dividend declaration, and director appointments. No voting results were included.
Ipca Laboratories Ltd reported revenue from operations of ₹2,788 Cr (+20.8% YoY) and net profit of ₹424.3 Cr (+82.2% YoY) for Q1 FY27.
Ipca Laboratories scheduled a Board meeting for August 13, 2026. The board will consider standalone and consolidated financial results for the first quarter.
Ipca Laboratories fixed August 7, 2026, as the record date for a Rs. 6 per share dividend. Payment will occur by September 10, 2026.
Ipca Laboratories will hold its 76th AGM on August 13, 2026, via video conferencing. The board recommended a Rs. 6 per share final dividend for shareholders.
Ipca Laboratories submitted its Business Responsibility and Sustainability Report for FY 2025-26. The report details environmental, social, and governance disclosures forming part of its Annual Report.
Ipca Laboratories released its Annual Report for FY 2025-26. The report includes financial highlights, the Directors' Report, and Business Responsibility & Sustainability reporting.
India Ratings & Research affirmed ratings on Ipca Laboratories' INR 22,481.10 million loan and INR 500 million CP, total Rs 2,298.11 crore. Ratings stay AA+ (loan) and A1+ (CP).
Ipca Laboratories approved the merger of Krebs Biochemicals with a 7:200 swap ratio. The move aims to integrate fermentation-based API manufacturing and secure key supply chains.
Ipca Laboratories approved the amalgamation of Krebs Biochemicals & Industries Ltd. The merger aims to optimize costs and secure API supplies.
Ipca Laboratories entered a global licensing pact with BRL for subcutaneous biologics delivery technology. This partnership targets affordable monoclonal antibody development for oncology and inflammatory diseases.
Ipca Labs reports 8% FY26 consolidated revenue growth to ₹9,646cr. Management focuses on margin improvement and volume-led growth in domestic and US markets.
Ipca Laboratories approved the re-appointment of Mr. Prashant Godha as Executive Director for five years. The 60-month term begins effective August 16, 2026.
Ipca Laboratories recommended a final dividend of Rs. 6 per share for FY 2025-26. The record date for payment is fixed for August 7, 2026.
Ipca Laboratories Ltd reported revenue from operations of ₹2,388 Cr (+6.3% YoY) and net profit of ₹306.7 Cr (+379.2% YoY) for Q4 FY26.
Ipca Laboratories reported FY26 consolidated net profit of ₹1,141.12 Crore. The board recommended a ₹6 per share dividend, signaling strong financial performance and shareholder returns.
Ipca Laboratories submitted its Annual Secretarial Compliance Report for the financial year 2025-26. The report confirms overall regulatory compliance with no material deviations or penalties.
Ipca Laboratories announced a Board of Directors meeting on May 29, 2026. The board will consider audited financial results for Q4 and FY26, alongside a dividend recommendation for FY26. The trading window remains closed until May 31, 2026.
Ipca Laboratories Limited submitted a compliance certificate for the quarter ended March 31, 2026, regarding the dematerialisation of securities. The certificate, issued by MUFG Intime India Pvt. Ltd., confirms that security certificates were processed and the depositories' names were updated within prescribed timelines. This is a routine regulatory disclosure.